Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the efficacy and safety profile of each agent when choosing the best therapeutic option for individual patients. Each agent targets tyrosine kinases within the cell uniquely to cause the desired antiproliferative effect. In addition to inhibiting the BCR-ABL kinase, imatinib and nilotinib target the same array of other tyrosine kinases, including c-KIT and plateletderived growth factor receptor (PDGFR), albeit with differing potencies. While targeting BCR-ABL with the highest potency among approved agents in CML, dasatinib also targets a broad array of off-target kinases, including SRC family members, PDGFR and EPHB4. The differences in kinase inhibition profiles among these agents in vitro probably account for the differing clinical safety profiles of these agents. This paper reviews the various kinases inhibited by imatinib, nilotinib and dasatinib, and describes the potential impact of kinase inhibition on the efficacy and safety of each agent.
Introduction
The introduction of the small tyrosine kinase inhibitor (TKI), imatinib, has revolutionized the treatment of chronic myeloid leukemia (CML). 1 Imatinib is a relatively specific inhibitor of BCR-ABL, the gene product of the t(9;22) chromosomal translocation event that forms the Philadelphia chromosome characteristic of CML and some acute lymphocytic leukemias. 2, 3 The fusion of BCR-ABL results in the constitutive activity of the ABL tyrosine kinase, which ultimately drives transformation of hematopoietic progenitor cells.
Imatinib was approved by the US Food and Drug Administration in 2002 for the first-line treatment of CML based on its high cytogenetic and molecular response rates, long-term efficacy and superior tolerability over interferon (IFN)-based therapy. 4, 5 Imatinib is widely accepted as the standard therapy for newly diagnosed chronic-phase CML patients in addition to all CML patients who have failed stem cell transplant or IFN-a therapy. 6, 7 Imatinib serves as a model for the utility of targeted agents in the treatment of cancer. For a relatively few CML patients, resistance to imatinib is present before, or develops during treatment. [8] [9] [10] [11] Several strategies are available to treat imatinib-resistant patients, including imatinib dose escalation, dose adjustment based on pharmacokinetic assessments and the use of novel TKIs ( Figure 1 , Table 1 ).
Nilotinib and dasatinib are potent inhibitors of BCR-ABL that are US Food and Drug Administration approved for the treatment of patients resistant to, or intolerant of, prior therapy, including imatinib. These second-generation TKIs have shown efficacy in all imatinib-resistant or -intolerant CML patients. [12] [13] [14] Thus far, nilotinib and dasatinib appear to be similar with regard to clinical efficacy, 15 although they display differential safety profiles. 16 Other new kinase inhibitors are in early clinical trials as alternatives to imatinib therapy, including bosutinib, MK-0457 and INNO-406 ( Figure 1 , Table 1 ). Larger prospective, randomized studies are needed to determine the place of these new therapies in the treatment algorithm of CML. However, the potential for increased potency of these drugs could eventually lead to their replacement of imatinib as first-line CML therapy. Although these new therapies are already changing the landscape of CML therapy, it is important to distinguish the differences between these agents regarding target kinase profile, safety and efficacy. This article will review the similarities and differences in the kinase inhibition profiles of imatinib, nilotinib, dasatinib and newer BCR-ABL kinase inhibitors, with a focus on the safety of each agent. Although no randomized clinical trials have been conducted comparing nilotinib and dasatinib treatments, one must use the data from the available studies to make an informed choice between the two agents for patients who have become resistant or intolerant to imatinib therapy. The following sections will highlight pre-clinical and clinical data to assist in choosing between the currently available second-generation agents.
Differential kinase inhibition profiles of TKIs in CML treatment
Inhibition of the BCR-ABL tyrosine kinase is considered to be the underlying mechanism of clinical activity of imatinib, nilotinib and dasatinib in the treatment of CML. As the first-generation TKI in this class of agents, imatinib inhibits BCR-ABL, albeit to a lesser extent than nilotinib or dasatinib. Imatinib also inhibits c-KIT and platelet-derived growth factor receptor (PDGFR) at clinically relevant concentrations (Table 1) . Nilotinib inhibits most imatinib-resistant BCR-ABL forms, except T315I, in vitro at concentrations approved for and tested in patients. 17 Nilotinib is 30-fold more potent than imatinib at inhibiting BCR-ABL (Table 2) . 18, 19 Early data on nilotinib in newly diagnosed CML patients suggest clinical activity with the potential to exceed first-line imatinib efficacy, pending longer follow-up data.
ABL-related kinase ARG, DDR1 kinase, the oxidoreductase NQO2, 20, 21 and has some activity against the ephrin receptor EPHB4, but displays no activity against the Src family of kinases. 13, 22 Similar to nilotinib, dasatinib also inhibits most imatinib-resistant BCR-ABL forms, except T315I, in vitro. 14, 23 However, it displays greater inhibition, with approximately 325-fold more potency than imatinib at inhibiting BCR-ABL (Table 2) . 14 Dasatinib also inhibits c-KIT and PDGFR with greater potency, and has a broad range of inhibitory activity against a number of other tyrosine kinases (Table 2), including  the ephrin receptor tyrosine kinase, Src and Src family kinases  (FGR, FYN, HCK, LCK, LYN and YES) . 22, 24 Lack of selectivity in binding Src family kinases probably derives from the fact that, unlike imatinib and nilotinib, dasatinib binds to the active conformation of the ABL kinase domain. In its active conformation, ABL bears remarkable structural resemblance to the Src family kinases. 25 Although both nilotinib and dasatinib have shown activity against a range of BCR-ABL kinase mutations, there exist a number of specific mutations that are less sensitive to each of these agents. For nilotinib, these mutations include E255K/V, Y253H, F359V and T315I, and for dasatinib, these mutations include Q252H, E255K/V, F317L, V299L and T315I. [26] [27] [28] The relationship of kinase inhibition profile with safety Wild-type ABL inhibition: cardiac events All currently approved TKIs for CML treatment inhibit wild-type ABL kinase. ABL is a key mediator of normal cardiac function and is expressed in the cardiac and other tissues ( Figure 2) . A link between the imatinib inhibition of ABL and cardiac events was first suggested by Kerkela et al. 29 In this retrospective study, 10 subjects with normal baseline cardiac function developed left ventricular dysfunction during imatinib therapy. Correlative studies in mice and cell lines revealed that imatinib-induced inhibition of ABL led to an endoplasmic reticulum stress response, collapse of the mitochondrial membrane potential, Figure 1 Structures of current and investigational tyrosine kinase inhibitors for the treatment of CML. 100 Adapted from Weisberg et al. Adapted from Redaelli et al.
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release of cytochrome c into the cytosol, reduction in cellular ATP content and apoptosis. 29 However, serious cardiac events associated with imatinib therapy are rare. In fact, a retrospective analysis of six imatinib monotherapy trials, comprising 2327 patients with 5595 years of patient exposure (median exposure duration, 2.4 years), revealed a congestive heart failure incidence of 0.2%. 30 Furthermore, retrospective analysis of the International Randomized Study of Interferon and STI571 (IRIS) in Chronic Myeloid Leukemia trial, which compared IFN þ cytarabine (Ara-C) with imatinib in 1106 newly diagnosed patients with CML in chronic phase (CP), found that the incident cases of cardiac failure and left ventricular dysfunction possibly or probably related to study medication exposure was 0.04% per year (1 case in 2309 years of patient exposure) for patients receiving imatinib vs 0.75% per year (4 cases in 536 years of patient exposure) in patients receiving IFN þ Ara-C. 30 More recently, a retrospective analysis of 219 patients with gastrointestinal stromal tumors or other sarcomas receiving imatinib therapy showed rare occurrence of congestive heart failure, observed in only one elderly patient with known prior cardiac disease. 31 Taken together, it appears that imatinib has little clinical impact on cardiac function.
Cardiac adverse events (AEs), including congestive heart failure, left ventricular dysfunction and QT prolongation, have all been reported with dasatinib and nilotinib, with the rates of left ventricular dysfunction highest with dasatinib. 32, 33 Further, 2% of patients in dasatinib clinical trials developed congestive heart failure or cardiac dysfunction. Of these cases, half were grade 3/4. 34 A systematic literature review of clinical trials using nilotinib 400 mg twice daily or dasatinib 70 mg twice daily revealed that grade 3/4 nonhematologic AEs, including arrhythmia, were more than 2-7 times higher for dasatinib compared with nilotinib, though the events occurred in o5% of the study population. 16 Despite the cardiac concerns for nilotinib and dasatinib, overall rates of QTcF interval changes4500 ms were low for both agents (o1%). 33, 35 Moreover, although cardiac events were present, albeit uncommon, in both dasatinib and nilotinib clinical trials, sudden death on nilotinib or dasatinib because of cardiac events has rarely been reported and can be further safeguarded against by performing baseline electrocardiogram. 36 Still, at this time, there is insufficient evidence to exclude a relationship between the rare occurrence of sudden death in patients treated with either nilotinib or dasatinib and cardiac AEs.
Src kinase inhibition: myelosuppression
Nilotinib does not inhibit the Src family of kinases at therapeutic doses. However, owing to its less selective binding capacity, dasatinib strongly inhibits Src and related kinases. These kinases are key signaling members in normal hematopoiesis. Five Src family members, HCK, LYN, FGR, LCK and BLK, are expressed only in hematopoietic cells. 37 HCK is critical for the development and survival of myeloid cells and B lymphocytes. LYN is expressed in all blood cell lineages except T cells and is required for B-cell development. [38] [39] [40] LYN is also an important modulator of erythropoiesis, as it positively modulates erythroid progenitor cell expansion to promote erythrocyte survival. 41 In fact, LYN knockout mice are anemic. 42 Although there is no clear clinical link between Src inhibition by dasatinib and myelosuppression, nilotinib, which does not inhibit the Src family of kinases, has a more favorable myelosuppression profile. Further, a review of clinical trial data reveals that rates of grade 3/4 hematologic AEs for dasatinib treatment were higher than those seen with nilotinib in both CML-CP and CML-advanced phase (AP) patients. 16, 43 Specifically, CML-CP patients displayed grade 3/4 neutropenia and thrombocytopenia at respective rates of 50 and 49% with dasatinib therapy, and 30 and 28% with nilotinib therapy. 44, 45 Overall, rates of myelosuppression are higher in CML-AP patients with both agents. However, rates of grade 3/4 anemia, neutropenia and thrombocytopenia were still higher in CML-AP patients receiving dasatinib: 70, 74 and 83%, respectively, compared with CML-AP patients receiving nilotinib: 27, 41 and 36%, respectively. 43 It should be noted that rates of hematologic AEs on dasatinib therapy improved with 100 mg once-daily dosing. In the dasatinib phase II dose optimization study, 100 mg oncedaily dosing significantly reduced the incidence of grade 3/4 thrombocytopenia (22 vs 37%; P ¼ 0.004) and reduced the rates of grade 3/4 anemia (10 vs 16%; P ¼ NS) and neutropenia (33 vs 42%; P ¼ NS). 46 It is unclear what effects could develop because of the long-term inhibition of Src in patients treated with dasatinib for extended periods of time.
PDGF inhibition: altered bone metabolism and fluid retention Altered bone metabolism. Hypophosphatemia can occur with imatinib and nilotinib therapy. Memorial Sloan-Kettering investigators observed hypophosphatemia among a small SPOTLIGHT Figure 2 ABL signaling and inhibition in cardiomyocytes. 101 In cardiomyocytes, imatinib induces ER stress, leading to the activation of the PKRlike ER kinase (PERK) and IRE1 pathways, and to the overexpression of protein kinase Cd (PKCd). PERK phosphorylates the eukaryotic translation initiation factor 2a (EIF2a) as part of a protective response, and on sustained ER stress, IRE1 activates Jun N-terminal kinases (JNKs), leading to the phosphorylation of 14-3-3 and release of BAX followed by mitochondrial depolarization, ATP depletion, cytochrome c (Cyt c) release, and features of necrotic and apoptotic cell death. Adapted from Force et al. 107 percentage of their CML patients enrolled in the IRIS trial (described in detail above). 47 In a subsequent case-control study, 16 of 24 (67%) CML patients developed hypophosphatemia on imatinib. Grade 3/4 hypophosphatemia rates of 10% have been reported for patients receiving nilotinib. 33 Patients with hypophosphatemia had elevated parathyroid hormone levels, low-to-normal serum calcium levels, high levels of phosphate excreted in the urine and decreased serum levels of osteocalcin and N-telopeptide of collagen cross-links, both of which are markers of bone resorption. It is hypothesized that inhibition of bone turnover by imatinib leads to low serum calcium and phosphate levels, which in turn causes increased parathyroid secretion and phosphate excretion in an attempt to maintain calcium homeostasis.
Platelet-derived growth factor receptor-a, a factor that decreases osteoblast development and activity and may alter bone metabolism, is known to be inhibited by imatinib and nilotinib. PDGFRa is highly expressed in cultured osteoprogenitors and osteoblasts, and plays a critical role in the development of rat skeleton. 48 The PDGF isoforms, PDGF-AA and PDGF-BB, stimulate replication 49 and migration 50 of rat osteoblasts in vitro. PDGF-BB also increases the number of rat osteoblasts in vivo. 51 In human and murine cells, osteoblast survival is thought be stimulated by PDGF-BB through the phosphorylation of Akt. 52 Therefore, a decrease in osteoclast development and activity may also result from imatinib and nilotinib therapy. In humans, mature osteoclasts are derived from the monocyte-macrophage lineage. 53 The maturation of macrophages into osteoclasts requires the activity of macrophage colony-stimulating factor secreted by stromal cells and osteoblasts, which binds to the colony-stimulating factor 1 receptor on macrophages. 54 In vitro studies show that macrophage colony-stimulating factor activation of colony-stimulating factor 1 receptor is inhibited by imatinib. 55 Although data are limited, and no mechanistic studies with nilotinib have been performed at this time, there is some evidence that PDGF-BB stimulates bone resorption by osteoclasts in humans directly through PDGFRb. 56 Thus, the inhibition of PRGFRb by imatinib may interfere with osteoclast-stimulated bone resorption. In addition to the effects of imatinib therapy described above, hypophosphatemia has been observed in patients with renal cell carcinoma on sunitinib 47 and in approximately 11% of CML-CP patients in clinical trials with dasatinib ( Figure 3) . 16 Therefore, abnormalities in bone metabolism may be a general class effect of TKIs that inhibit PDGFR.
Fluid retention. Platelet-derived growth factor receptor inhibition also affects fluid retention and serosal inflammation (pleural effusions). PDGFRb is expressed in pericytes 57 and lung tissue, and is involved in the regulation of angiogenesis. 58 Inhibition of PDGFR has been well documented to induce changes in intratumoral interstitial pressures and fluid homeostasis among the tumor compartment, vascular compartment and extracellular space. 59 These changes may explain why patients who receive PDGFR inhibitors develop edema and third spacing of fluid (mobilization of fluid to a location within the body, rendering it unavailable to the circulatory system). By contributing to edema and volume increase in patients, PDGFR inhibition may also tax the cardiovascular system and induce cardiotoxicity by indirectly straining the heart. Imatinib-associated peripheral edema is primarily superficial. 60 Serosal inflammation resulting in anasarca, pleural or pericardial effusion or ascites is rare with imatinib, occurring in 1% of CML-CP and 3% of CML-blast phase (BP) patients. 61 Nilotinib inhibits PDGFR with a potency similar to that of imatinib and the incidence of edema in nilotinib-treated patients is also rare. 33 An 11% rate of grade 1/2 peripheral edema was observed in CML-CP patients enrolled in nilotinib phase II trials and no patients had grade 3/4 peripheral edema. Occurrence of anasarca, pleural or pericardial effusion and ascites was also extremely rare. Serosal inflammation, specifically, pleural effusion, is more common in CML patients treated with dasatinib therapy, with rates of any grade pleural effusion ranging between 14 and 35%. Rates of pleural effusion can be especially high among patients with advanced CML. In patients who have failed imatinib and received dasatinib therapy, rates of grade 3/4 pleural effusion were found to be as high as 19% in CML-CP patients and 28% in CML-myeloid blast crisis patients. [62] [63] [64] All of the aforementioned data are from dasatinib dosing at 70 mg twice daily and it should be noted that the incidence of grade 3/4 pleural effusions, but not the overall incidence, was significantly decreased with the widely used 100 mg once-daily dosing of dasatinib (16 vs 7%; P ¼ 0.024). 46 The high rates of pleural effusion with dasatinib therapy may be related to its potent inhibition of PDGFRb (IC 50 , 28 nmol/l). 65, 66 The lesser degree of PDGFRb inhibition by imatinib and nilotinib may explain the significantly lower incidence of pleural effusion with these agents compared with dasatinib. 67, 68 Recent evidence suggests that the peripheral edema seen with imatinib and the pulmonary edema associated with dasatinib may be because of distinct mechanisms. In a recent cohort study of 43 CML-CP patients, generalized fluid retention was not a significant predictor of pulmonary edema. 69 The only variables found to be predictive of pulmonary edema in a multivariate analysis were a history of autoimmune disease (relative risk, 13; 95% confidence interval, 1.6-103) and dasatinib dose (relative risk 7.4; 95% confidence interval, 1.2-44.3). These results suggest that dasatinib-induced pulmonary edema does not correlate with generalized fluid retention and may instead be mediated by an immune mechanism. The findings also suggest that the inhibition of PDGFR alone may not be sufficient to cause serosal inflammation, but that the combined inhibition of Src (affecting vascular permeability) and PDGFR (affecting interstitial fluid pressure and vascular permeability) could be a contributing factor to the high incidence of pleural effusions with dasatinib. Notably, bosutinib, a dual Src and ABL inhibitor with little activity against PDGFR, has not been associated with pleural effusion. 70, 71 Src inhibition may also mediate fluid retention. Vascular permeability mediated by vascular endothelial growth factor is directly dependent on Src kinases that are widely expressed in lung tissues. 72, 73 Src also regulates focal adhesions and adherens junctions, which may be involved in the stability of the pleural epithelium and pleural space homeostasis. 74, 75 As Src kinases are inhibited by dasatinib with an IC 50 of 0.5 nM, it is reasonable to hypothesize that Src kinase inhibition by dasatinib may contribute to fluid retention observed in treated patients. 37, 65, 66 Other risk factors for pulmonary edema on dasatinib include prior cardiac history, hypertension and twice-daily administration of dasatinib. 62 Other risk factors include advanced disease (BP4AP4CP), previous lung problems (smoking and infections) and in those maintained on starting doses of dasatinib. 76 
c-KIT inhibition: dermatologic toxicity, myelosuppression and other adverse events
The c-KIT receptor is an important target in the treatment of various solid tumor types and hematologic malignancies. In SPOTLIGHT these cancers, high levels of c-KIT result from overexpression of the protein or mutations in the KIT gene. In most gastrointestinal stromal tumor cases, c-KIT is constitutively activated. 77 Activated forms of c-KIT have also been found in a number of other malignancies, including mast cell disorders, seminomas and acute myelogenous leukemia. 78 Dermatologic toxicity. Cutaneous reactions, including superficial edema and skin rash, are the most common nonhematologic side effects found with imatinib therapy. 5 In a study of 118 CML patients on imatinib therapy, superficial edema and rash were observed in 48 and 12.7% of patients, respectively. 79 There was also a high prevalence of pigmentary changes, which included 40.9% depigmentation (localized or generalized) and 3.6% hyperpigmentation. Pigmentary changes, skin rash and related events are most likely due to imatinib inhibition of c-KIT in the skin. c-KIT is normally expressed in skin basal cells, melanocytes, epithelial cells of the breast, tissue mast cells and other cells. 80 Recent data suggest that c-KIT has a major role in melanogenesis, melanocyte homeostasis and ultraviolet B-induced pigmentation. 81 Myelosuppression. c-KIT is essential for the development of normal blood cells, melanocytes and mast cells. 82, 83 The degree of c-KIT inhibition by imatinib, nilotinib and dasatinib seems to correlate with the rates of myelosuppression seen with each agent. With the identification of c-KIT as a potential target for anticancer therapy, there were concerns that AEs might preclude their utility in the anticancer armamentarium. Although it is still unclear whether the inhibition of c-KIT plays a direct role in some of the clinical AEs observed with c-KIT inhibitors, several AEs reported with imatinib, nilotinib and dasatinib are consistent with c-KIT inhibition, including myelosuppression. Despite these safety concerns, the clinical activity of imatinib SPOTLIGHT Figure 3 Molecular determinants of hypophosphatemia in patients treated with PDGFR inhibitors. 41 M-CSF, macrophage colony-stimulating factor; PDGF, platelet-derived growth factor; RANK, receptor activator of NF-kB; RANKL, receptor activator of NF-kB ligand. Adapted from Berman et al. 47 and nilotinib in gastrointestinal stromal tumor has been attributed to their inhibitory effects on the c-KIT receptor. 84, 85 Clinical implications of differential target kinase profiles of imatinib, nilotinib and dasatinib Imatinib has a favorable safety profile with an overall low incidence of grade 3/4 AEs in newly diagnosed CML-CP patients. Rash, fatigue, headache, nausea, diarrhea, and muscle and joint pain are the most frequently reported drug-related events. Less than 3% of patients report grade 3/4 events. 5 Grade 3/4 superficial edema is also infrequent and occurs in less than 1% of patients. Imatinib treatment does result in myelosuppression, including grade 3/4 neutropenia (14.3%), thrombocytopenia (7.8%) and anemia (3.1%). A longer-term follow-up of the IRIS study (described above in detail) has not significantly changed the safety profile of imatinib. 86 Imatinib is overall well tolerated. However, some patients require further treatment with a second-generation TKI because of resistance to, or intolerance of, imatinib.
Nilotinib and dasatinib are both highly active in CML-CP patients who have failed imatinib because of resistance or intolerance. 44, 45, 64, 87 However, their safety profiles differ substantially (Tables 3 and 4 ). The most common nonhematologic grade 3/4 adverse events for patients with CML-CP treated with nilotinib include lipase elevation (16%), bilirubin elevation (7%) and hyperglycemia (12%). The increases in serum glucose were not clinically significant and no patient discontinued study drug because of hyperglycemia. Lipase elevations were transient and asymptomatic; however, patients with an earlier history of pancreatitis should have lipase checked periodically. Conversely, headache and diarrhea related to study drug appear to be more frequent in dasatinib-treated patients. Importantly, more patients treated with dasatinib experience fluid retention. The incidence of peripheral edema is threefold greater in 70 mg twice-daily dasatinib-treated patients compared with that in 400-600 mg twice-daily nilotinib (18 vs 6%, respectively). Pleural effusions were also more frequently noted with dasatinib treatment (19%) compared with nilotinib (1.2%) treatment. Finally, hematologic AEs were more frequent in dasatinibtreated patients, with nearly half the patients receiving 70 mg twice-daily dasatinib experiencing grade 3/4 neutropenia and thrombocytopenia. Dasatinib treatment was also associated with bleeding events, reported in 16% of all patients and in 4% experiencing grade 3/4 AEs. 44, 88 In a separate study, 81% of all bleeding episodes occurred in the gastrointestinal tract, with a median time of 6 weeks to development of bleeding. 89 Dasatinib treatment has also been shown to induce plateletaggregation effects when compared with imatinib, nilotinib or bosutinib treatment. 90 The low frequency of bleeding events observed with nilotinib makes it a good choice for patients with risk factors for bleeding complications. Overall, it is important to consider that much of the current literature on dasatinib-related AEs focuses on the 70 mg twice-daily dose, but it is important to keep in mind that the 100 mg once-daily dose is now widely used and significantly reduces the number of several AEs, including grade 3/4 pleural effusion and thrombocytopenia. 46 A major therapeutic advantage of nilotinib is the absence of any significant cross-intolerance with imatinib. 91, 92 Nilotinib as subsequent treatment is very well tolerated by the majority of patients with imatinib intolerance (Table 5) . Recurrence of similar grade 3/4 AEs during nilotinib therapy was observed in less than 1% (1/71) and 18%, 7 of 38 patients with nonhematologic and hematologic imatinib intolerance, respectively. All the patients who experienced nonhematologic imatinib intolerance were CML-CP patients experiencing thrombocytopenia. 91, 92 During secondary dasatinib therapy, approximately 4%, 9 of 225 patients with nonhematologic, and 13%, 6 of 46 patients with hematologic imatinib intolerance experienced recurrence of similar grade 3/4 AEs. 93, 94 In this study, reoccurrence of grade 3/4 hematologic toxicity was observed in 86%, 37 of 43 patients. Cross-intolerance of dasatinib treatment is most typically a result of neutropenia and/or thrombocytopenia. [95] [96] [97] [98] [99] [100] Patients who switched to dasatinib because of imatinib intolerance subsequently discontinued dasatinib due to intolerance at similar levels to nilotinib.
Taken together, nilotinib appears to have a greater overall favorable safety profile with regard to fluid retention, myelosuppression and bleeding events, and shows little crossintolerance with imatinib in imatinib-intolerant patients. When selecting a second-generation TKI for patients with imatinib resistance or intolerance, the safety of the therapy should help guide the treatment decision for each individual patient. Table 3 Incidence of nonhematologic adverse events reported for nilotinib and dasatinib in STUDY 2101 and START-C trials, respectively However, other considerations are also important and must be accounted for in the decision-making process, including the patient's mutation status, the differential pharmacokinetic profile and dosing schedule of the therapy, concomitant medications and likely adherence to therapy, among others.
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Emerging agents in the treatment of CML
Bosutinib (SKI-606) is an oral dual Src/Abl TKI capable of 200-fold greater BCR-ABL inhibition compared with imatinib (Table 2) . Unlike imatinib, bosutinib does not show any appreciable activity against c-KIT or PDGFR. 71 As bosutinib is also an inhibitor of Src kinase, it may have a safety profile similar to dasatinib. Interestingly, no patients in a phase I/II bosutinib study experienced pleural effusion or pulmonary edema. 70 This could be because of the fact that bosutinib is a weaker inhibitor of PDGFR. 71 At the moment, the greatest safety challenge with bosutinib appears to be the high level of grade 3/4 diarrhea that must be managed appropriately to ensure treatment continuation. MK-0457 is a moderate-to-strong inhibitor of ABL and JAK2, and a robust inhibitor of aurora kinase and FLT3. 101 Notably, MK-0457 is the only secondgeneration TKI to show efficacy against the BCR-ABL T315I mutation in vitro. 102 In November 2007, patient enrollment into phase I and II MK-0457 trials was suspended, pending a full analysis of all efficacy and safety data after one patient displayed QTc prolongation. INNO-406, which is structurally related to imatinib and nilotinib, strongly inhibits both BCR-ABL and LYN. This dual inhibition may be significant as acquired imatinib resistance is thought to be mediated in part through LYN overexpression. In vitro analysis of INNO-406 showed 20-fold greater potency than imatinib and inhibited several imatinibresistant BCR-ABL mutants, but not T315I. In addition to BCR-ABL, INNO-406 also inhibits PDGFR and c-KIT to a similar degree as imatinib. INNO-406 has no effect on Src, 24, 103 and as a result, may have a safety advantage over dasatinib. INNO-406 was well tolerated in phase I trials of heavily pre-treated CML-AP patients who failed prior therapy, including imatinib, because of resistance and intolerance. [104] [105] [106] More clinical data are needed to determine if INNO-406 will benefit CML patients. Overall, the prospects of combining currently approved TKIs with emerging therapies that are active against the T315I mutation are of particular interest, given the potential for combination therapy of CML treatment in the future.
Overall, there appears to be an emerging pattern of TKI kinase selectivity profiles in the treatment of CML being closely linked to their respective safety profiles. Currently, nilotinib and imatinib exhibit the most selective kinase inhibition profiles, as well as the most favorable safety profiles, and are excellent therapeutic options for patients with CML. Future studies will determine how the emerging therapies with varied target kinase profiles will also fit into the CML treatment paradigm.
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